CA-SYNACK
Synack, the most trusted Crowdsourced Penetration Testing company, announced today it is now both CREST Accredited for penetration testing services and a CREST Member company in the USA. This is further recognition of Synack as the market leader in delivering the most effective, efficient penetration test.
CREST is a not-for-profit accreditation and certification body that represents and supports the technical information security market. CREST was set up in 2006 in response to the clear need for more regulated professional services with known, dependable quality, and is now recognized globally as the cyber assurance body for the technical security industry. CREST has become the respected standard for penetration testing in countries across the world, where it is increasingly a mandatory requirement for companies that have the most stringent security requirements such as government and financial services. Synack has researchers in more than 60 of these countries.
“This accreditation demonstrates that Synack’s crowdsourced penetration testing follows well-established best practices while using software and the world’s best security researchers,” said Dr. Mark Kuhr, Synack CTO and co-founder. “CREST’s accreditation examination determines if an organization meets its risk assessment, technical capability, and code of conduct standards. The CREST organisation clearly understands the challenges enterprises face today in scaling their security practices, and is supporting the G2000 by accrediting Synack to support these challenges. We appreciate the acknowledgement that Synack meets all of those critical requirements.”
Synack has prioritized trust, quality and insights as critical characteristics of a penetration test. The accreditation process determines if an organization meets risk assessment, technical capability, and code of conduct standards. Relative to a traditional penetration test, Synack believes that the crowdsourced approach provides additional testing rigor, enhanced technology, and deeper visibility and control.
“The CREST accreditation provides further recognition of Synack penetration testing, offering the highest levels of technical quality and testing rigor“ said David Charlton, Synack’s Chief Product Strategist and former Head of Penetration Testing at JPMorgan Chase & Co.
Not only does CREST offer an independent, third party assessment of a company’s penetration testing capabilities, it also provides researchers with the opportunity to become CREST qualified researchers. Synack’s crowd includes CREST certified penetration testers. Synack exposes its elite, global security researcher community in 60+ countries to the benefits of CREST. CREST offers a structured entry point for penetration testers globally and could serve as a significant stepping stone to members of the Synack’s Red Team. Synack looks forward to working closely with members of its global community seeking CREST qualifications.
This accreditation is another pillar showing that Synack takes trust seriously. Companies gain intelligence and efficiency by utilizing Synack to address vulnerabilities in a more efficient and effective way while maintaining a strong security posture. Those that work with Synack and use Crowdsourced Penetration Testing for 2+ years are up to 200% more secure than those that do not or have less than a year of usage.
Today, Synack secures >$1 trillion in Fortune 500 revenue, 75% of the top credit card companies, Top 10 consulting firms and security companies, and over 50% of federal cabinet-level agencies. Synack has received awards including 2019 Cyber Defender by CB Insights, CIO Review’s 20 Most Promising Enterprise Security Solution Providers, The Software Report’s Top 25 CyberSecurity Companies, and Wealthfront’s 2019 Career-Launching Companies.
About Synack
Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005215/en/
Contact:
Ellie McCardwell, Synack Communications Email: press@synack.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom